Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HBB | P68871 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23646288 | 0.90 | HSD17B10 (0.45) | FGFR1SRCASIC3ADORA1MEN1 | |
| SCHEMBL1901873 | 0.83 | KDM4E (0.45) | FGFR1SRCADORA1MEN1KMT2A | |
| SCHEMBL29972990 | 0.83 | KDM4E (0.45) | FGFR1SRCADORA1MEN1KMT2A | |
| SCHEMBL21223615 | 0.80 | ADORA2B (0.47) | ADORA1MEN1MAPK1KMT2ALMNA | |
| SCHEMBL27550199 | 0.80 | PDE10A (0.54) | ASIC3ADORA1KMT2ABACE1LMNA | |
| SCHEMBL21223550 | 0.78 | BACE1 (0.44) | FGFR1SRCADORA1MEN1CYP3A4 | |
| SCHEMBL21223602 | 0.78 | MAP4K4 (0.50) | ADORA1BACE1CYP1A2KCNH2ALDH1A1 | |
| SCHEMBL11008096 | 0.78 | NOS3 (0.50) | ASIC3MEN1MAPK1KMT2ABACE1 | |
| SCHEMBL28335499 | 0.78 | MEN1 (0.51) | ADORA1MEN1MAPK1KMT2ABACE1 | |
| SCHEMBL3180674 | 0.78 | FGFR1 (0.46) | FGFR1SRCADORA1MEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210221784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | UNIVERSITÉ DE STRASBOURG (FR) | 2021-07-22 | — | — | US | claimed |
| EP-3749305-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | Université de Strasbourg (FR) | 2020-12-16 | — | — | EP | claimed |
| CN-111683660-A | Compounds and compositions for the treatment of pain | 斯特拉斯堡大学 | 2020-09-18 | — | — | CN | claimed |
| WO-2019149965-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | UNIVERSITE DE STRASBOURG (FR) | 2019-08-08 | — | — | WO | claimed |
| EP-3442947-B1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | EPIZYME INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210221784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | UNIVERSITÉ DE STRASBOURG (FR) | 2021-07-22 | — | — | US | disclosed |
| US-20210221784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | UNIVERSITÉ DE STRASBOURG (FR) | 2021-07-22 | — | — | US | disclosed |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2021-07-01 | — | — | US | disclosed |
| EP-3749305-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | Université de Strasbourg (FR) | 2020-12-16 | — | — | EP | disclosed |
| CN-111683660-A | Compounds and compositions for the treatment of pain | 斯特拉斯堡大学 | 2020-09-18 | — | — | CN | disclosed |
| CN-111494378-A | Compositions and methods for treating proliferative disorders | 艾科尔公司 | 2020-08-07 | — | — | CN | disclosed |
| CN-107074769-B | Compositions and methods for treating proliferative disorders | 艾科尔公司 | 2020-04-07 | — | — | CN | disclosed |
| CN-107074769-A | Compositions and methods for treating proliferative disorders | 艾科尔公司 | 2017-08-18 | — | — | CN | disclosed |
| WO-2016161572-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016161572-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | disclosed |
| CN-103748093-A | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE INC | 2014-04-23 | — | — | CN | disclosed |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2011082270-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE. INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-4229456-A | SUPPRESSION OF GASTRIC SECRETIONS | MERCK & CO., INC. (US) | 1980-10-21 | — | — | US | disclosed |
| US-4133885-A | GASTRIC SECRETIONS INHIBITORS | MERCK & CO., INC. (US) | 1979-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | ACHE, TRPV1, OPRL1 | FGFR1 3626/4885SRC 638/4885ASIC3 142/4885 |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | FGFR1 4648/4885SRC 1984/4885ASIC3 4487/4885 |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | FGFR1 880/4885SRC 302/4885ASIC3 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.